Schrodinger, Inc.
SDGR · XNASCIK 1490978fmd_1R92BP5PJV2PBJ9TV5CPX40JD4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 86 | 108 | 138 | 181 | 217 | 208 | 256 |
| Cost of revenue | 36 | 45 | 72 | 80 | 76 | 75 | 113 |
| Gross profit | 49 | 63 | 66 | 101 | 141 | 132 | 143 |
| Research and development | 39 | 65 | 91 | 126 | 182 | 202 | 173 |
| Selling, general and administrative | 48 | 60 | 86 | 121 | 136 | 140 | 136 |
| Total operating expenses | 88 | 124 | 177 | 248 | 318 | 341 | 310 |
| Operating income | (39) | (61) | (111) | (147) | (177) | (209) | (167) |
| Interest and investment income | 2 | 2 | 1 | 4 | – | – | – |
| Other non-operating income (expense) | 13 | 35 | 11 | (2) | 220 | 24 | 65 |
| Income before taxes | (26) | (26) | (101) | (149) | 43 | (186) | (102) |
| Income tax expense | (0) | 0 | 0 | 0 | 2 | 1 | 1 |
| Net income from continuing operations | (26) | (27) | (101) | (149) | 41 | (187) | (103) |
| Net income | (25) | (24) | (100) | (149) | 41 | (187) | (103) |